896 related articles for article (PubMed ID: 29364151)
1. Insights into the Molecular Mechanisms of Alzheimer's and Parkinson's Diseases with Molecular Simulations: Understanding the Roles of Artificial and Pathological Missense Mutations in Intrinsically Disordered Proteins Related to Pathology.
Coskuner-Weber O; Uversky VN
Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29364151
[TBL] [Abstract][Full Text] [Related]
2. Intrinsically disordered proteins in various hypotheses on the pathogenesis of Alzheimer's and Parkinson's diseases.
Coskuner O; Uversky VN
Prog Mol Biol Transl Sci; 2019; 166():145-223. PubMed ID: 31521231
[TBL] [Abstract][Full Text] [Related]
3. Structures of the intrinsically disordered Aβ, tau and α-synuclein proteins in aqueous solution from computer simulations.
Nguyen PH; Derreumaux P
Biophys Chem; 2020 Sep; 264():106421. PubMed ID: 32623047
[TBL] [Abstract][Full Text] [Related]
4. A Fragment-Based Method of Creating Small-Molecule Libraries to Target the Aggregation of Intrinsically Disordered Proteins.
Joshi P; Chia S; Habchi J; Knowles TP; Dobson CM; Vendruscolo M
ACS Comb Sci; 2016 Mar; 18(3):144-53. PubMed ID: 26923286
[TBL] [Abstract][Full Text] [Related]
5. Epitope region identification challenges of intrinsically disordered proteins in neurodegenerative diseases: Secondary structure dependence of α-synuclein on simulation techniques and force field parameters.
Mandaci SY; Caliskan M; Sariaslan MF; Uversky VN; Coskuner-Weber O
Chem Biol Drug Des; 2020 Jul; 96(1):659-667. PubMed ID: 31903719
[TBL] [Abstract][Full Text] [Related]
6. Synergistic Amyloid Switch Triggered by Early Heterotypic Oligomerization of Intrinsically Disordered α-Synuclein and Tau.
Bhasne K; Sebastian S; Jain N; Mukhopadhyay S
J Mol Biol; 2018 Aug; 430(16):2508-2520. PubMed ID: 29704492
[TBL] [Abstract][Full Text] [Related]
7. Structures and free energy landscapes of the A53T mutant-type α-synuclein protein and impact of A53T mutation on the structures of the wild-type α-synuclein protein with dynamics.
Coskuner O; Wise-Scira O
ACS Chem Neurosci; 2013 Jul; 4(7):1101-13. PubMed ID: 23607785
[TBL] [Abstract][Full Text] [Related]
8. Non-Amyloid-β Component of Human α-Synuclein Oligomers Induces Formation of New Aβ Oligomers: Insight into the Mechanisms That Link Parkinson's and Alzheimer's Diseases.
Atsmon-Raz Y; Miller Y
ACS Chem Neurosci; 2016 Jan; 7(1):46-55. PubMed ID: 26479553
[TBL] [Abstract][Full Text] [Related]
9. α-Synuclein misfolding and aggregation: Implications in Parkinson's disease pathogenesis.
Mehra S; Sahay S; Maji SK
Biochim Biophys Acta Proteins Proteom; 2019 Oct; 1867(10):890-908. PubMed ID: 30853581
[TBL] [Abstract][Full Text] [Related]
10. Crucial role of protein oligomerization in the pathogenesis of Alzheimer's and Parkinson's diseases.
Choi ML; Gandhi S
FEBS J; 2018 Oct; 285(19):3631-3644. PubMed ID: 29924502
[TBL] [Abstract][Full Text] [Related]
11. α-synuclein-assisted oligomerization of β-amyloid (1-42).
Chau E; Kim JR
Arch Biochem Biophys; 2022 Mar; 717():109120. PubMed ID: 35041853
[TBL] [Abstract][Full Text] [Related]
12. Generation and characterization of novel conformation-specific monoclonal antibodies for α-synuclein pathology.
Vaikath NN; Majbour NK; Paleologou KE; Ardah MT; van Dam E; van de Berg WD; Forrest SL; Parkkinen L; Gai WP; Hattori N; Takanashi M; Lee SJ; Mann DM; Imai Y; Halliday GM; Li JY; El-Agnaf OM
Neurobiol Dis; 2015 Jul; 79():81-99. PubMed ID: 25937088
[TBL] [Abstract][Full Text] [Related]
13. Modulation of Disordered Proteins with a Focus on Neurodegenerative Diseases and Other Pathologies.
Martinelli AHS; Lopes FC; John EBO; Carlini CR; Ligabue-Braun R
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30875980
[TBL] [Abstract][Full Text] [Related]
14. Amyloid Oligomers: A Joint Experimental/Computational Perspective on Alzheimer's Disease, Parkinson's Disease, Type II Diabetes, and Amyotrophic Lateral Sclerosis.
Nguyen PH; Ramamoorthy A; Sahoo BR; Zheng J; Faller P; Straub JE; Dominguez L; Shea JE; Dokholyan NV; De Simone A; Ma B; Nussinov R; Najafi S; Ngo ST; Loquet A; Chiricotto M; Ganguly P; McCarty J; Li MS; Hall C; Wang Y; Miller Y; Melchionna S; Habenstein B; Timr S; Chen J; Hnath B; Strodel B; Kayed R; Lesné S; Wei G; Sterpone F; Doig AJ; Derreumaux P
Chem Rev; 2021 Feb; 121(4):2545-2647. PubMed ID: 33543942
[TBL] [Abstract][Full Text] [Related]
15. Exploring Structural Insights of Aβ42 and α-Synuclein Monomers and Heterodimer: A Comparative Study Using Implicit and Explicit Solvent Simulations.
Varenyk Y; Theodorakis PE; Pham DQH; Li MS; Krupa P
J Phys Chem B; 2024 May; 128(19):4655-4669. PubMed ID: 38700150
[TBL] [Abstract][Full Text] [Related]
16. Transition Metal Ion Interactions with Disordered Amyloid-β Peptides in the Pathogenesis of Alzheimer's Disease: Insights from Computational Chemistry Studies.
Strodel B; Coskuner-Weber O
J Chem Inf Model; 2019 May; 59(5):1782-1805. PubMed ID: 30933519
[TBL] [Abstract][Full Text] [Related]
17. How an Infection of Sheep Revealed Prion Mechanisms in Alzheimer's Disease and Other Neurodegenerative Disorders.
Carlson GA; Prusiner SB
Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34064393
[TBL] [Abstract][Full Text] [Related]
18. Biophysical studies of protein misfolding and aggregation in
Sinnige T; Stroobants K; Dobson CM; Vendruscolo M
Q Rev Biophys; 2020 Jun; 49():e22. PubMed ID: 32493529
[TBL] [Abstract][Full Text] [Related]
19. Long-range correlated dynamics in intrinsically disordered proteins.
Parigi G; Rezaei-Ghaleh N; Giachetti A; Becker S; Fernandez C; Blackledge M; Griesinger C; Zweckstetter M; Luchinat C
J Am Chem Soc; 2014 Nov; 136(46):16201-9. PubMed ID: 25331250
[TBL] [Abstract][Full Text] [Related]
20. Biophysics of Parkinson's disease: structure and aggregation of alpha-synuclein.
Uversky VN; Eliezer D
Curr Protein Pept Sci; 2009 Oct; 10(5):483-99. PubMed ID: 19538146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
